Objective-Lp(a) [lipoprotein(a)] is a well-described risk factor for atherosclerosis, but Lp(a)-associated risk may vary by race/ethnicity. We aimed to determine whether race/ethnicity modifies Lp(a)-related risk of carotid atherosclerotic plaque outcomes among black, white, Chinese, and Hispanic individuals. Approach and Results-Carotid plaque presence and score were assessed by ultrasonography at baseline (n=5155) and following a median 9.4 year period (n=3380) in MESA (Multi-Ethnic Study of Atherosclerosis) participants. Lp(a) concentrations were measured by immunoassay and examined as a continuous and categorical variable using clinically-based cutoffs, 30 and 50 mg/dL. Lp(a) was related to greater risk of prevalent carotid plaque at baseline in whites alone (all P<0.001): per log unit (relative risk, 1.05); Lp(a)≥30 mg/dL (relative risk, 1.16); and Lp(a)≥50 mg/dL (relative risk, 1.20). Lp(a) levels over 50 mg/dL were associated with a higher plaque score at baseline in whites (all P<0.001) and Hispanics (P=0.04). In prospective analyses, whites with Lp(a) ≥50 mg/dL were found to have greater risk of plaque progression (relative risk, 1.12; P=0.03) and higher plaque scores (all P<0.001) over the 9.4-year follow-up. Race-based differences between whites and black participants were significant for cross-sectional associations and for carotid plaque score following the 9.4 year study period. 
C ardiovascular risk guidelines from the American College of Cardiology Foundation/American Heart Association and the European Society of Cardiology/ European Atherosclerosis Society affirm that circulating levels of Lp(a) (Lipoprotein [a] ) are an independent risk factor for atherosclerotic cardiovascular disease (ASCVD). 1, 2 Both recent consensus panels and the 2018 American Heart Association/American College of Cardiology Guideline on the Management of Blood Cholesterol have recommended Lp(a) assessment for individuals at intermediate to high risk of ASCVD 3, 4 and in children with a family history of familial hypercholesterolemia. 5 Despite guideline and panel recommendations as well as the nearly ten thousand Lp(a) studies conducted to date, there remain ongoing controversies regarding Lp(a)-related risk and clinical testing.
Currently, there is no universal clinical cutoff value for Lp(a) that discriminates increased risk of ASCVD development. Although clinical laboratories in the United States designate elevated Lp(a) levels at 30 mg/dL, the American Heart Association/American College of Cardiology and European guidelines recommend a threshold of 50 mg/ dL. 3, 4 Further complicating this designation, Lp(a) may differentially confer risk of ASCVD outcomes depending on race/ ethnicity. [6] [7] [8] [9] It has been reported that Lp(a) is a significant risk factor for calcific aortic valve disease in white and black participants, but not in Hispanics or Chinese Americans. 6 Lp(a) has further been shown to be related to greater risk of incident heart failure in white individuals. 7 Finally, Lp(a) has been associated with risk of peripheral artery disease in Hispanics and whites, but not in black or Chinese Americans. 9 Although no studies have examined race-based differences in Lp(a) and carotid plaque development, research in largely homogeneous populations and with other subclinical atherosclerosis outcomes have shown inconsistent results so far. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] Given the present gaps in the literature, we aimed to interrogate 2 clinical Lp(a) cutoff values and examine whether race/ethnicity serves as a modifying variable for Lp(a) and risk of carotid atherosclerotic plaque in MESA (Multi-Ethnic Study of Atherosclerosis) participants. The findings may provide additional justification for inclusion of Lp(a) in clinical guidelines, and any observed race/ethnicity-based differences would inform future recommendations and consensus panels.
Materials and Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.
Study Population
MESA was begun to investigate the prevalence and progression of subclinical cardiovascular disease in individuals free of known clinical cardiovascular disease, radiation or chemotherapy-treated cancer, other serious major illnesses, or cognitive impairment in the judgment of the screening interviewer before baseline. 27 Between 2000 and 2002, 6814 men and women without cardiovascular disease, aged 45 to 84 years, and of white, black, Hispanic, or Chinese racial/ethnic backgrounds were enrolled from 6 communities. Institutional Review Board approval was obtained at all MESA sites, and all participants gave informed consent. Further MESA protocol information is available at www.mesa-nhlbi.org.
Demographic, Anthropometric, and Clinical Measurements
Questionnaires were used to obtain information regarding age, sex, race/ethnicity, education, and lifestyle factors including smoking status, physical activity, and dietary intake. Height and weight were measured by trained staff according to standard procedures, and body mass index was calculated as weight (kg)/height (m 2 ). Resting blood pressure was measured using the Dinamap Monitor PRO 100 (Critikon, Tampa, Florida) automated oscillometric device; 3 measures were taken; the last 2 measures were averaged and recorded.
Laboratory Measurements
Fasting blood was drawn and collected in EDTA-anticoagulant tubes. Samples were aliquoted and stored at −70°C until analyte measurements were conducted. Fasting total cholesterol and HDL-C (high-density lipoprotein cholesterol) concentrations were measured as described previously. 28 Lp(a) mass concentration was assessed using a latex-enhanced turbidimetric immunoassay (Denka Seiken, Tokyo, Japan) that controls for the size heterogeneity of apo(a) [apolipoprotein(a)]. 29 Images of the right and left common, bifurcation, and internal carotid arterial segments were obtained and converted into digital records. Images were interpreted by the MESA Carotid Ultrasound Reading Center at the University of Wisconsin. Carotid plaque was defined as focal thickening at least 50% greater than the surrounding intima media or a discrete, focal wall thickening ≥1.5 cm. Kappa values for intra-reader and inter-reader reproducibility of carotid plaque were respectively 0.83 (95% CI, 0.70-0.96) and 0.89 (95% CI, 0.72-1.00).
Statistical Model
Statistical analysis was conducted using Stata (version 15.0, Stata Corp, College Station, TX). Baseline characteristics were presented as means (SD) for continuous variables with normal distributions, medians (interquartile ranges) for continuous variables with skewed distributions, and frequencies (%) for categorical variables. Tukey-Kramer honestly significant difference was used to test differences between groups. Lp(a) was examined as a continuous variable (per log unit) and as a categorical variable using 2 clinical cutoff values (30 and 50 mg/dL). Generalized linear model with log link function was used to estimate the relative risk per log unit of Lp(a) for the presence of carotid plaque and its progression with 95% CIs. These outcomes were examined as logistical variables. Carotid plaque score was assessed by the number of carotid plaques (0-12) at both baseline and at the follow-up exam, a median 9.4 years after baseline. Ordered logit regression was used to determine associations of Lp(a) and plaque score. The study sample was stratified by race/ethnicity, and statistical adjustments were made for age, sex, hypertension medication use, lipid-lowering medication use, systolic blood pressure, smoking status (never, former, or current) diabetes mellitus (as defined by American Diabetes Association criteria), total cholesterol, and HDL-C. Individuals with missing covariate data were excluded from analyses. Of the 5271 participants with baseline ultrasound data, 116 were missing one or more covariates, leaving 5155 participants for cross-sectional analyses. Of the 3441 participants with ultrasound measurements at both baseline and at the follow-up exam, 61 were missing one or more covariates, leaving 3380 participants for prospective analyses. Lp(a)-race interactions were examined by including race/ethnicity as an interaction term in the above regression models. Interactions were deemed significant where P<0.10.
Results
Characteristics of the 5271 MESA participants of this subcohort are shown in Table 1 and are further stratified by prevalent baseline carotid plaque. Individuals with carotid plaque were more likely to be older, male, white, former or current smokers, taking hypertension or lipid-lowering medication, have diabetes mellitus, higher systolic blood pressure, and higher levels of blood lipids including Lp(a) (all P<0.001). The study sample was additionally stratified by race/ethnicity (Table I in the online-only Data Supplement). Across the 4 races/ethnicities, significant differences were observed in clinical and lifestyle characteristics including Lp(a) and carotid plaque. Black individuals had the highest median Lp(a) levels (P<0.001) whereas whites showed the highest prevalence of carotid plaque at baseline and following 9.4 years (both P<0.001). Lp(a) distributions of the MESA cohort for each race/ethnicity are presented in Figure IA through ID in the online-only Data Supplement.
Cross-sectional relations of Lp(a) and baseline carotid plaque are shown in Table 2 . Greater Lp(a) levels were related to significantly greater risk of plaque in whites, irrespective of whether Lp(a) was examined as a continuous or categorical variable (all P<0.001). Both clinical cutoff values discriminated risk of plaque in whites. Including race/ethnicity as an interaction term showed significant differences in relations of Lp(a) and prevalent carotid plaque between white and black participants; Lp(a)≥30 mg/dL (P for interaction=0.02), and Lp(a)≥50 mg/dL (P for interaction=0.01).
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Cross-sectional associations of Lp(a) and baseline carotid plaque score as determined by total plaque number are shown in Table 3 . Greater Lp(a) levels were related to significantly greater plaque score in whites, irrespective of whether Lp(a) was examined as a continuous or categorical variable (all P<0.001). A significant relationship was also found in Hispanics with Lp(a) ≥50 mg/ dL (P=0.04). Including race/ethnicity as an interaction term showed differences in relations of Lp(a) and carotid plaque score between white and black participants: per log unit of Lp(a) (P for interaction=0.10), Lp(a)≥30 mg/ dL (P for interaction=0.007), and Lp(a)≥50 mg/dL (P for interaction=0.001).
Prospective associations between Lp(a) and risk of carotid plaque progression over the mean 9.4-year study period are shown in Table 4 . Lp(a)-related risk of plaque progression was only found in whites with Lp(a) levels ≥50 mg/dL. There was no race significant interactions.
Prospective associations of Lp(a) and plaque score following a median period of 9.4 years are shown in Table 5 . Greater 
Discussion
In a multi-ethnic cohort, Lp(a) was found to be significantly related to all carotid plaque outcomes in whites. Significant race interactions were observed between black and white individuals for all outcomes except plaque progression. The absence of a race interaction with plaque progression was likely because of a combination of factors including the selection bias for healthier individuals in the follow-up sample and that the ordinal plaque score variable has a power advantage over the logistical plaque progression outcome-facilitating the identification of an interaction when examining the former. Null findings were largely observed in the other races/ethnicities, though associations of Lp(a) with prevalent plaque outcomes were statistically borderline in Hispanics. For Hispanic participants, it must be acknowledged that Hispanic does not represent a homogeneous race, and genetic/ancestral overlaps with European, African, and Native American populations have been reported. 30 Indeed, it has been estimated that Hispanic Americans may share >65% ancestry with European Americans. 30 This large degree of overlap may translate to similarities in Lp(a) pathogenicity, which contributed to the borderline results observed here. By contrast, despite the ≈3-fold higher median Lp(a) levels in black individuals, no relations between Lp(a) and carotid plaque outcomes were found in this group or in Chinese Americans. Although this is the first multi-ethnic cohort study to interrogate Lp(a) and carotid atherosclerotic plaque, other studies have examined Lp(a) and carotid plaque as well as other measures of subclinical coronary atherosclerosis.
Previous Studies
To date, few large cohort studies have examined Lp(a) and carotid atherosclerosis, but positive associations have been reported in smaller samples. In studies of patient populations, 11,12 a subanalysis of 152 AIM-HIGH clinical trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) subjects, 13 and subcohort studies, 10, 14 Lp(a) has been shown to increase risk of carotid atherosclerosis outcomes including stenosis, Risk ratios and 95% CIs are shown, P values were significant. Covariate adjustments were made for age, sex, systolic blood pressure, hypertension and lipidlowering medication use, total cholesterol, HDL-C, diabetes mellitus, and smoking status. Race-interactions were tested between racial/ethnic groups. Diabetes mellitus: treated and untreated cases; smoking status: current, former, and never. HDL-C indicates high-density lipoprotein-cholesterol; and Lp(a), lipoprotein(a).
*Carotid plaque progression was modeled as a logistical variable (0 or 1) progression was considered to have occurred when a new plaque developed after baseline. †No significant race-interactions were observed. ‡P values.
occlusion, and plaque burden. Most relevant to the present findings, a cross-sectional analysis in the biracial ARIC (Atherosclerosis Risk in Communities) cohort showed that Lp(a) was related to greater carotid wall thickness in both black and white individuals in an age-adjusted model. 31 Although no race interactions were identified in the ARIC study, methodological differences may have contributed to the inconsistency with the present findings. Among these, the carotid wall thickness outcome used in ARIC is a composite value of extracranial common carotid artery, internal carotid artery, and carotid bifurcation intima-media thicknesses and is less precise than the carotid plaque variable used here. In addition, Lp(a) assessment in the ARIC study may have been another source of imprecision as it predated an important methodological advancement in measuring Lp(a). It is now recognized that either controlling for apo(a) isoform size heterogeneity or using an apo(a) isoform size-insensitive assay is crucial for obtaining accurate Lp(a) values. Taken together, differences in the outcome and exposure variables may have contributed to the null race interaction in ARIC and their identification here.
In contrast to studies of carotid atherosclerosis, those of Lp(a) and risk of coronary atherosclerosis as assessed by coronary artery calcification have offered equivocal findings. Lp(a) has been shown to be unrelated to coronary artery calcification in a number of cohort studies 16, 17 including MESA 6 and the Dallas Heart Study, 15 but also in smaller studies of black individuals 18 and postmenopausal women. 24 Although the above null findings are counter to Lp(a) increasing risk of coronary atherosclerosis in the general population, there is evidence that Lp(a) is related to coronary artery calcification in subgroups with underlying ASCVD risk factors. Specifically, Lp(a)-related risk of coronary artery calcification has been reported in European patients with chest pain, 23 healthy black individuals with a family history of early-onset coronary artery disease, 25 European individuals with a family history of ASCVD, 26 hypercholesterolemia patients, 21, 22 females with diabetes mellitus, 17 and male smokers. 19 Collectively, these studies provide nuanced evidence that Lp(a) is related to coronary atherosclerosis but appear to dispute the established causal role of Lp(a) in coronary events such as myocardial infarction. And yet, as proposed by Nordestgaard and Langsted, 32 Lp(a) likely promotes coronary events by contributing to thrombosis and stenosis and not early atherogenesis, which is supported by the above study findings. Indeed, it must be acknowledged that our results in the carotid vascular bed may be more consistent with a role for Lp(a) promoting stenosis than inducing early atherogenesis. As this remains a controversial area in Lp(a) research, further studies are warranted.
Implications and Further Research
The race-based differences in Lp(a) and risk of carotid plaque affirm previous observations that Lp(a) may be more pathogenic in whites and potentially Hispanic individuals compared with black or Chinese Americans for certain cardiovascularrelated outcomes, 6, 7, 9 though not all. 8 Given recent advances in Lp(a) lowering therapies such as proprotein convertase subtilisin/kexin type 9 inhibitors and antisense oligonucleotides, it is possible that these pharmacotherapies may be more efficacious in whites and Hispanics in reducing a broader range of cardiovascular outcomes than in other populations.
A biological/biochemical explanation for the observed race-based differences remains uncertain, but there are a number of possibilities. Previous research has demonstrated that the kringle IV (KIV) type II domain of the Lp(a) component, apo(a), differs by race/ethnicity and influences circulating levels of Lp(a), [33] [34] [35] but our results suggest that properties of Lp(a) other than circulating concentrations may contribute to its atherogenecity. Indeed, a number of heterogeneous regions of apo(a) have been identified. 36 Of these, the KIV 10 domain influences lysine residue binding, 37 has been shown to affect vascular cell permeability in tissue culture, 38 and defects in KIV 10 were found to lower apo(a)/Lp(a) vascular accumulation and reduce atherogenecity in experimental murine models. 39, 40 Genetic heterogeneity in KIV 10 may, therefore, be expected to have implications for risk of atherogenesis or stenosis. In addition to KIV 10 domain variations, race-based differences in Lp(a) oxidation would also lead to differences in atherogenic burden. However, the 1 prospective cohort Regression coefficients and 95% CIs are shown, P values were significant or approaching significance. Covariate adjustments were made for age, sex, systolic blood pressure, hypertension and lipid-lowering medication use, total cholesterol, HDL-C, diabetes mellitus, and smoking status. Raceinteractions were tested among racial/ethnic groups. Diabetes mellitus: treated and untreated cases; smoking status: current, former, and never. HDL-C indicates high-density lipoprotein-cholesterol; and Lp(a), lipoprotein(a).
*Modeled as an ordinal variable with plaque score values from 0 to 12. †Significantly different than black participants (P for interaction <0.10). ‡Significantly different than white participants (P for interaction <0.10). §P values.
study to examine this phenomenon showed that oxidized Lp(a) levels are greater in black individuals compared with whites, 41 which would refute such a mechanism-though confirmation studies are warranted. Finally, it is well-documented that Lp(a) localizes to atherosclerotic plaques [42] [43] [44] [45] [46] ; however, there remains a paucity of data across different races/ethnicities, and analyzing carotid plaque composition in other races would be appropriate. Taken together, additional research of Lp(a) particle biochemistry and its localization to atherosclerotic plaques may provide insights into putative race-based differences in Lp(a) pathogenicity observed here.
Strengths and Limitations
The present analysis represents the first cohort study showing a modifying influence of race/ethnicity on Lp(a) and risk of carotid atherosclerotic plaque. The study was well-powered in terms of sample sizes and numbers of carotid plaque cases in both cross-sectional and prospective analyses. Although the study design does not permit the determination of causality, the mean 9.4-year study period allowed for the assessment of temporality of associations. In terms of limitations, Lp(a) is likely related to ASCVD risk depending upon the vascular bed or event outcome similar to other lipid and nonlipid risk factors. 47, 48 Therefore, race-based differences in Lp(a) and risk of carotid plaque should not be generalized to other vascular beds or event outcomes. It must also be recognized that there was a selection bias for healthier individuals in the prospective analyses since these participants completed a follow-up visit a median 9.4 years after baseline. The sample showed a lower rate of incident cardiovascular disease, which may have contributed to the weaker findings for the plaque progression outcome. Finally, statistical adjustments were made for typical ASCVD risk factors, but the possibility of confounding cannot be excluded.
Conclusions
The race was found to be a modifying variable in Lp(a)-related risk of carotid atherosclerotic plaque, and Lp(a) levels may have greater influence on plaque burden in whites than in black individuals. Borderline results in Hispanics suggest that elevated Lp(a) may increase risk of carotid plaque, but follow-up studies are needed. Collectively, these results have implications for the role of Lp(a) in influencing ASCVD risk across different races, and additional studies are warranted to continue exploring differences in the molecular biochemistry and pathogenicity of Lp(a) particles among races/ethnicities.
